RecruitingPhase 3NCT07190222
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
Sponsor: Sanofi
Austin, TX · Dallas, TX · Denison, TX · +73 more sites